Compare BioNano Genomics Inc (BNGO) vs CarMax, Inc (KMX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs CarMax, Inc — how do they compare? BioNano Genomics Inc trades at $1.17 (market cap $13.20M), while CarMax, Inc trades at $59.28 (market cap $7.91B). The key difference: CarMax, Inc is far larger — about 599.2× BioNano Genomics Inc's market cap, and CarMax, Inc is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| BNGO | KMX | |
|---|---|---|
Market Cap | $13.20M | $7.91B |
Sector | Health | Consumer Cyclical |
52-Week High | $4.92 | $63.53 |
52-Week Low | $1.09 | $30.88 |
Enterprise Value | $15.81M | $26.42B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.
BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.
CarMax (KMX) trades at $54.87, up 2.58% today, with a bullish technical signal from moving averages and a neutral oscillator stance. The company reported Q1 2026 earnings that beat expectations, with EPS of $0.34 versus $0.23 expected, driven by cost controls and strategic execution. Revenue for 2025 was $26.35 billion, with net income of $500.56 million, though margins remain thin. Recent news highlights a four-pillar turnaround strategy under new CEO Keith Barr, with insider buying and positive analyst updates supporting sentiment.
The outlook for KMX hinges on successful execution of its growth strategy amid competitive pressures and margin challenges. While technical indicators suggest near-term strength, fundamental risks include high debt levels and fluctuating profitability. Analyst consensus is cautious with a hold-heavy rating, but the stock offers potential for recovery if operational improvements sustain. Investors should weigh the bullish technical setup against fundamental headwinds and ongoing investigations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About CarMax, Inc
CarMax sells, finances, and services used and new cars through a chain of over 230 used retail stores. It was formed in 1993 as a unit of Circuit City and spun off into an independent company in late 2002. Used-vehicle sales typically account for about 83% of revenue and wholesale about 13%, with the remaining portion composed of extended service plans and repair. In fiscal 2022, the company retailed and wholesaled 924,338 and 706,212 used vehicles, respectively. CarMax is the largest used-vehicle retailer in the U.S. but still estimates that it has only about 4% U.S. market share of vehicles 0-10 years old in 2021. It seeks over 5% share by the end of calendar 2025 and revenue between $33 billion to $45 billion by fiscal 2026. CarMax is based in Richmond, Virginia.
Read more on KMX →
